Phathom Pharmaceuticals, Inc. Accrued Expenses

Accrued Expenses of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Accrued Expenses growth rates and interactive chart. Accrued expense is expense which has been incurred but not yet paid. Expense must be recorded in the accounting period in which it is incurred. Therefore, accrued expense must be recognized in the accounting period in which it occurs rather than in the following period in which it will be paid.


Highlights and Quick Summary

  • Accrued Expenses for the quarter ending September 29, 2021 was $21.7 Million (a -7.01% decrease compared to previous quarter)
  • Year-over-year quarterly Accrued Expenses decreased by -29.66%
  • Annual Accrued Expenses for 2020 was $30.9 Million (a 1149.09% increase from previous year)
  • Annual Accrued Expenses for 2019 was $2.48 Million (a 1252.46% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Accrued Expenses of Phathom Pharmaceuticals, Inc.

Most recent Accrued Expensesof PHAT including historical data for past 10 years.

Interactive Chart of Accrued Expenses of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Accrued Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $21.75 $23.39 $17.75
2020 $30.92 $16.9 $6.56 $3.24 $30.92
2019 $2.48 $4.45 $2.48
2018 $0.18 $0.18

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.